Company profile

Bolt Biotherapeutics, Inc.

Pipeline5 assets

BDC-4182BDC-4182 / Claudin 18.2 / Boltbody ISAC / Oncology
Gastric cancerPhase 1Ongoing dose-escalationGastroesophageal cancerPhase 1Ongoing dose-escalation
BDC-3042BDC-3042 / Dectin-2 / Agonist monoclonal antibody / Oncology
Non-small cell lung cancer, melanoma and other solid tumorsPhase 1Dose-escalation complete; seeking partner
CEA ISACCEA/CEACAM5 / Boltbody ISAC / Oncology
Colorectal, non-small cell lung, pancreatic and gastric cancersPreclinicalPre-IND; seeking partner
PD-L1 ISACPD-L1 / Boltbody ISAC / Oncology
Solid tumors resistant to checkpoint inhibitorsPreclinicalPre-IND; seeking partner
Caprin-1 ISACCaprin-1 / Boltbody ISAC / Oncology

Latest news3 items

May 12, 2026

Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 Phase 1/2 study ongoing, initial clinical data expected in 3Q 2026 Cash balance of $23.9 million as of March 31, 2026 anticipated to fund operations into 2027, including completion of the dose escalation portion of the ongoing BDC-4182

Mar 12, 2026

Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business Update

First-in-class immune-stimulating antibody conjugate BDC-4182 in Phase 1 dose escalation study, initial clinical data expected in 3Q 2026 Cash balance of $31.8 million as of December 31, 2025 anticipated to fund key milestones into 2027 REDWOOD CITY, Calif., March 12, 2026 (GLOBE NEWSWIRE) -- Bolt

Feb 24, 2026

Bolt Biotherapeutics to Participate in Upcoming March Conferences

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that management will participate in two upcoming conferences in March: TD Cowen 46th